摘要
目的探讨止风定哮汤联合普米克令舒治疗咳嗽变异性哮喘的临床疗效。方法选取2018年3月—2021年3月在齐齐哈尔市中医医院南院呼吸内一科就诊的300例咳嗽变异性哮喘患者为研究对象,采用单盲分层随机对照的研究方法将患者分为A组、B组和C组,A组患者口服止风定哮汤联合普米克令舒吸入治疗,B组患者单纯口服止风定哮汤治疗,C组患者单纯普米克令舒雾化吸入治疗,对比3组患者过敏反应相关指标(血清IgE、EOS、ECP)、生活质量评分(LCQ评分)及肺通气功能(FEV1、FVC、PEF)。结果治疗前,3组患者过敏反应相关指标、生活质量LCQ评分和肺通气功能相关指标比较,差异无统计学意义(P>0.05);治疗后3组患者各项指标比较,A组治疗后IgE、EOS、ECP水平分别为(56.41±18.42)IU/mL,(0.05±0.10)×10^(9)/L,(5.98±1.12)μg/L显著低于B组和C组,差异有统计学意义(t=14.362、6.054、12.712、9.500、4.709、10.061,P<0.05);A组LCQ评分为(18.47±2.34)分,FEV1、FVC、PEF水平分别为(3.22±0.47)L、(4.15±0.51)L、(4.35±0.58)L/s,均显著优于B组和C组,差异有统计学意义(t=12.650、11.433、5.553、5.797、5.491、3.996、4.885、4.826,P<0.05);但B组和C组比较,差异无统计学意义(P>0.05)。结论止风定哮汤联合普米克令舒治疗咳嗽变异性哮喘能够有效抑制过敏因子释放,显著提高患者的生活质量,并有助于改善患者肺功能状态。
Objective To explore the clinical efficacy of Zhifeng Dingxiao decoction combined with Pulmicort Respulas in the treatment of cough variant asthma.Methods 300 patients with cough variant asthma treated in the respiratory department of the South Hospital of Qiqihar Traditional Chinese Medicine Hospital from March 2018 to March 2021 were selected as the research object.The patients were divided into group A,group B and group C by single blind stratified randomized control.Patients in group A were treated with oral Zhifeng Dingxiao decoction combined with Pulmicort Respulas inhalation,and patients in group B were treated with oral Zhifeng Dingxiao decoction alone.The patients in group C were treated with Pulmicort Respulas aerosol inhalation alone.The allergic reaction related indexes(serum IgE,EOS,ECP),quality of life score(LCQ score)and pulmonary ventilation function(FEV1,FVC,PEF)were compared among the three groups.Results Before treatment,there were no statistically significant differences in related indexes of allergic reaction,LCQ score of quality of life and related indexes of pulmonary ventilation function among 3 groups(P>0.05).After treatment,the IgE,EOS and ECP levels in group A were(56.41±18.42)IU/mL,(0.05±0.10)×10^(9)/L and(5.98±1.12)μg/L,respectively,significantly lower than those in group B and GROUP C,the difference was statistically significant(t=14.362,6.054,12.712,9.500,4.709,10.061,P<0.05).LCQ score of group A was(18.47±2.34)points,FEV1,FVC and PEF levels were(3.22±0.47)L,(4.15±0.51)L and(4.35±0.58)L/s,respectively,which were significantly better than group B and GROUP C.The difference was statistically significant(t=12.650,11.433,5.553,5.797,5.491,3.996,4.885,4.826,P<0.05).However,there was no statistically significant difference between group B and group C(P>0.05).Conclusion Zhifeng Dingxiao decoction combined with Pulmicort Respulas in the treatment of cough variant asthma can effectively inhibit the release of allergic factors,significantly improve the quality of life of patients,and
作者
王雪飞
杨艳华
孟巍
WANG Xuefei;YANG Yanhua;MENG Wei(Department of Respiratory Medicine,South Hospital of Qiqihar Traditional Chinese Medicine Hospital,Qiqihar,Heilongjiang Province,161005 China)
出处
《系统医学》
2022年第13期1-4,共4页
Systems Medicine
基金
齐齐哈尔市科技计划创新激励项目(CSFGG-2021203)。
关键词
止风定哮汤
普米克令舒
咳嗽变异性哮喘(风哮型)
疗效
Zhifeng Dingxiao Decoction
Pulmicort Respulas
Cough variant asthma(fengxiao type)
Curative effect
